Health‐related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial by Ketty Peris, Timothy J. Inocencio, Alexander J. Stratigos, Karl D. Lewis, Zeynep Eroglu, Anne Lynn S. Chang, Cristina Ivanescu, Aleksandar Sekulic, Matthew G. Fury, Chieh‐I Chen, Ruben G. W. Quek

Get full text

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial by Celeste Lebbe, Omid Hamid, Shailender Bhatia, Janice M Mehnert, Patrick Terheyden, Michele Milella, Isaac Brownell, Sandra P D'Angelo, Andrew S Brohl, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Marcis Bajars, Gülseren Güzel, Paul T Nghiem

Get full text

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1) by Lucy Gilbert, Jameel Muzaffar, Vamsidhar Velcheti, Anna Spreafico, Emiliano Calvo, David F McDermott, Marc S Ernstoff, Valentina Boni, Karl D Lewis, Ira Winer, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Christoper J Hoimes, Seth D Rosen, Debora S Bruno, James F Strauss, Rita Dalal, Ulka N Vaishampayan, Quincy S Chu

Get full text